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Abstract
Objective: the main objective was to assess body composition in terms of skeletal muscle index (SMI), myosteatosis, visceral adipose tissue 
(VAT), subcutaneous adipose tissue (SAT), and intermuscular adipose tissue (IMAT) as an adjunct of information provided by radiotherapy CT 
planning scan. 
Material and methods: a sample of 49 patients with lung and digestive cancers underwent a CT scan for radiotherapy treatment, which included 
measurements at the L3 region. Images were analyzed with a radiotherapy contouring software, using different Hounsfield Unit (HU) settings. 
Cross-sectional areas (cm2) were automatically computed by summing tissue pixels and multiplying by pixel surface area. Low SMI (cm2/m2) and 
muscle density (HU) were determined according to the recently established cut-off points.
Results: the prevalence of low SMI was detected in 46.94% of patients, being present in 8 women, 4 men with BMI < 25 kg/m2, and 11 men with BMI 
≥ 25 kg/m2. The average mean skeletal attenuation of total skeletal muscle area was 29.02 (± 8.66) HU, and myosteatosis was present in 13 women 
(81.25%) and 31 men (93.94%). Mean SAT was 131.92 (± 76.80) cm2, mean VAT was 133.19 (± 85.28) cm2, and mean IMAT was 11.29 (± 12.86) cm2.
Conclusion: skeletal muscle abnormalities are frequently present in cancer patients and a low SMI may also exist even in the presence of 
overweight. As CT scans are an important tool at any radiation oncology department, they could also be used to offer highly sensitive and specific 









Objetivo: evaluar la composición corporal mediante el índice de músculo esquelético (IME), el tejido adiposo visceral (TAV), el tejido adiposo 
subcutáneo (TAS) y el tejido adiposo intermuscular (TAIM) o la densidad muscular (DM) en pacientes oncológicos antes de iniciar el tratamiento 
con radioterapia mediante cortes de TAC. 
Materiales y métodos: se estudiaron 49 pacientes con cáncer de pulmón y del aparato digestivo sometidos a tomografía computarizada con 
cortes en L3 para la determinación del tratamiento con radioterapia. El tejido adiposo y muscular se cuantificó mediante distintas Unidades 
Hounsfield (UH) (-29 a +150 para masa muscular, -190 a -30 para TAIM/TAS y -150 a -50 para TAV).
Resultados: la prevalencia de un IME bajo se detectó en el 46,94% de los pacientes, estando presente en 8 mujeres, 6 de ellas con un IMC ≥ 25 
kg/m². Según la distribución masculina, se identificaron 4 hombres con IMC < 25 kg/m² y 11 hombres con ≥ 25 kg/m². La DM media fue 
de 29,02 (± 8,66) UH y la mioesteatosis estuvo presente en 13 mujeres (81,25%) y 31 hombres (93,94%). La media del TAS fue de 131,92 
(± 76,80) cm², la del TAV de 133,19 (± 85,28) cm² y la del TAIM de 11,29 (± 12,86) cm².
Conclusión: las anormalidades del músculo esquelético y la masa grasa son muy frecuentes en los pacientes con cáncer, pudiendo existir un bajo IME 
incluso en presencia de sobrepeso u obesidad. Teniendo en cuenta que la TAC es una herramienta importante en cualquier departamento de radioterapia, 
también podría utilizarse para ofrecer información sensible y específica sobre la composición corporal, así como para detectar la malnutrición precoz.
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INTRODUCTION
Patients with cancer often have important nutritional deficien-
cies that significantly affect their quality of life, and the inciden-
ce of malnutrition increases as the disease progresses, until it 
affects 80% of patients (1). Sarcopenia is the loss of skeletal 
muscle mass with an increase in functional impairment and phy-
sical disability (2). According to an international group gathered 
to define sarcopenia in cancer patients, it is a fundamental part 
of cancer cachexia and an important part of the cancer patient 
evaluation (3). On the other hand, it is known that decreased 
muscle mass (MM) in cancer patients, also called pre-sarcope-
nia, increases the toxicity levels of treatment and therefore leads 
to treatment interruptions, dose reductions, and a higher risk of 
mortality (2,3,4).
In addition, muscle depletion is characterized by a reduction 
in muscle size and an increased proportion of intermuscular 
and intramuscular fat, denominated “myosteatosis” (5). This 
pathological problem has been relatively recently characteri-
zed; however, interest has been raised by its relationship to 
insulin resistance, poor physical function, and more recently 
poor survival (5,6).
On the other hand, sarcopenia is not restricted to people who 
are thin or cachectic (6,7). The condition called sarcopenic obe-
sity has been reported to have higher rates of complications and 
hospital costs when compared to patients with normal weight, 
an observation in accord with the obesity paradox (8). Moreo-
ver, cancer patients with sarcopenic obesity had the poorest 
prognosis (9). Historically, bioelectrical impedance analysis (BIA), 
body mass index (BMI), triceps skin fold, and serum albumin 
or prealbumin levels have been used as indicators for detec-
ting malnutrition (10). However, anthropometric quantification 
methods have a significant inter- and intra-observer variability, 
and this may limit sensitivity for detecting muscle changes and 
sarcopenic obesity (2,10,11). 
However, considering that we are in an age of technology ba-
sed on imaging techniques, computed tomography (CT) scans, 
which have long been used for the diagnosis of cancer, are 
becoming forefront strategies for nutritional assessment and 
intervention (12).  
Nowadays, it is known that the cross-sectional areas of tis-
sue in a single image at the third lumbar vertebra appear to 
be strongly correlated to whole-body adipose tissue and lean 
tissue mass (13). Due to these findings, body composition as 
skeletal muscle mass (SMM) and area of visceral adipose tissue 
(VAT), subcutaneous adipose tissue (SAT), and intermuscular 
adipose tissue (IMAT) can be accurately estimated using this 
approach (12). 
As muscularity and adiposity were associated with their own 
risk for poor health outcomes in cancer patients, our main goal 
in this study was to detect pre-sarcopenia and myosteatosis, as 
well as to assess the presence of VAT, SAT, and IMAT using the 
powerful information provided by CT planning scans in cancer 
patients evaluated for radiation treatment. 
MATERIAL AND METHODS
PATIENTS 
A sample of 49 patients referred for radiation oncology treat-
ment with lung cancer and tumors affecting the digestive system 
(esophagus, stomach, pancreas, gallbladder, rectum, and anus) 
were retrospectively analyzed between 2015 and 2017. All pa-
tients underwent virtual tomography with a SIEMENS Somaton 
Sensation Open CT planning scan (120 KV) for radiotherapy treat-
ment preparation, with measurements at the level of the L3 area. 
Patients without clinical data or without suitable CT examinations 
were excluded from the study.
The following clinical characteristics at the time of the CT 
scan were recorded: age ( > 18 years), tumor stage, secondary 
pathologies, weight, height, surgery, dose of radiation, type of 
chemotherapy, and surgical outcome. Body mass index (BMI) in 
kg/m2 was calculated according to weight and height, and there 
were applied different categories to classify patients: < 18.45, 
underweight; 18.5 kg/m2 to 24.9 kg/m2, normal weight; 25.0 
kg/m2 to 29.9 kg/m2, overweight; and ≥ 30.0 kg/m2, obese.
SKELETAL MUSCLE AND ADIPOSE TISSUE 
AREA MEASUREMENTS 
The cross-sectional area of the skeletal muscle mass area, 
subcutaneous adipose tissue area, visceral adipose tissue area, 
and intermuscular adipose tissue, including skeletal attenuation 
of the skeletal muscle area, were measured using CT scans at the 
level of the third lumbar vertebra (L3) (Fig. 1). This region contains 
different muscles including the psoas and paraspinal muscles, 
transversus abdominis, external and internal obliques of the abdo-
men, and rectus abdominis, as well as visceral, subcutaneous and 
intermuscular adipose tissue. All images for the study were used 
for the measurements and planning of the radiotherapy treatment 
(without extra patient radiation). 
Images were analyzed with a radiotherapy contouring software 
(MIM® 6.7 Inc., Cleveland, OH, USA) using different Hounsfield 
Unit (HU) thresholds, these being -29 to +150 for SMM, -190 to 
-30 for SAT and intermuscular adipose tissue (IMAT), and -150 
to - 50 for VAT (13,14). 
Cross-sectional areas (cm2) were automatically computed by 
summing tissue pixels and multiplying the result by their surface 
area (slice thickness range: between 1.5 mm and 3 mm). The data 
obtained were normalized by height (cm2/m2). The skeletal muscle 
index (SMI) (cm2/m2) was determined according to the currently 
established cut-off points, these being ≤ 41 cm2/m2 for women, 
≤ 53 cm2/m2 for men with BMI ≥ 25, and ≤ 43 cm2/m2 for men 
with BMI < 25 kg/m2 (15). Low muscle density (myosteatosis) was 
detected according to HU, and was < 33 for women and < 41 
for men (5,16). 
Examples of how the different tissue areas were measured with 
the MIM® software are shown in figure 2.
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Figure 2.
Body composition analysis. The CT analysis was made by contouring every tissue of interest on the L3 image. Different tissue densities were measured in Hounsfield Units 
(HU), these being -29 to +150 for SMM (pink color), -190 to -30 for SAT (blue color) and IMAT (green color), and -150 to -50 for VAT (orange color). As fat is more infiltrated 
inside muscles, its density (HU) decreases, so muscle density may also be measured according to the HU obtained for skeletal muscle mass. After the tagging process, the 
cross-sectional areas of tissues (cm2) were automatically computed by summing tissue pixels and multiplying by pixel surface area. 
Figure 1.
Determination of the third lumbar vertebra (L3). An isolated CT image from the third lumbar vertebra (L3) was used for the body measurements. The chosen image was the 
one with both transverse processes clearly visible, right in the middle of L3. All abdominal images were ordered for radiotherapy tumor treatment. All images were analyzed 
using the anonymous mode. Poor-quality and unsuitable CT scans were not included for the body analysis. 
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For the assessment of cross-sectional areas an automatic, 
software-driven identification and delineation method was used, 
manually corrected after automatic coloring, instead of free hand 
delineation, which may overestimate the results. 
STATISTICAL ANALYSIS 
The different variables contained in the study were analyzed with 
descriptive statistics, and the continuous variables were represented 
by mean, median, standard deviation and percentiles. The adjust-
ments of variables to normality were done with the Shaphiro-Wilk 
test. The statistical program STATA 14 was used for the analysis.
ETHICAL CONSIDERATIONS 
All CT images were used for the measurements and planning 
of the radiotherapy treatment (without extra radiation). Our retros-
Table I. Clinical and demographic characteristics of patients
Clinical feature of variable Number of cases (%)















































































COPD: chronic obstructive pulmonary disease; TB: tuberculosis; HIV: human immunodeficiency virus; HCV: hepatitis C virus; Chemo-RT: chemoradiotherapy.
pective study was approved by the Ethics Committee; however, 
because all images were used in an anonymized mode and can-
cer patients have a high risk of morbidity, the informed consent 
was not necessary according to the Law and ‘Best Practice’ 
guidelines. 
RESULTS
A sample of 49 patients (16 women, 33 men) were enrolled 
in this retrospective study. Patients had different cancer loca-
tions – lung (28.57%), esophagus (20.41%), stomach (18.37%), 
pancreas (12.24%), gallbladder (6.12%), rectum (10.20%), and 
anus (4.08%).
The clinical and demographic characteristics of the patients, 
including cancer stage,  classification of malignant tumors (TNM) 
according to the American Joint Committee on Cancer Staging 
manual (7th edition), secondary pathologies, type of treatment, 
and surgery outcomes are shown in table I.
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The mean age of patients was 65 years (range, 32-84 years), 
mean weight was 66.75 (± 11.25) kg, and mean BMI was 24.66 
(± 3.98) kg/m2. In terms of muscle and fat composition of these can-
cer patients before radiotherapy, mean SMM was 123.81 (± 34.01) 
cm2, mean SAT was 131.92 (± 76.80) cm2, mean VAT was 133.19 
(± 85.28) cm2, and mean IMAT was 11.29 (± 12.86) cm2 (Table II). 
Considering the distribution by gender, mean female weight was 60.9 
(± 10.09) kg and most of the women were within the normal BMI 
range, with an average of 24.23 (± 4.24) kg/m2 according to their 
BMI. As per males, mean weight was 69.98 (± 10.44) kg, also with 
a normal average according to their BMI – 24.83 (± 3.90) kg/m2 
(Table III).
On the other hand, skeletal muscle abnormalities were frequent-
ly present in cancer patients before radiotherapy. The prevalence 
of low SMI was detected in 46.94% of the sample – 8 women 
(50%) and 15 men (45.45%). Amongst the women with low SMI, 6 
(37.50%) had a BMI ≥ 25 kg/m2, and were considered sarcopenic 
obese. Amongst men, 4 (12.12%) had a BMI < 25 kg/m2 and 11 
(33.33%) had a BMI ≥ 25 kg/m2, these being sarcopenic obese 
as well (Fig. 3). Mean average SMI was 45.51 (10.33) cm/m2. The 
mean skeletal attenuation of total skeletal muscle area was 29.02 
(± 8.66) HU. This fact shows that myosteatosis was present in 
89.79% of patients. Of these, 26.53% (13 patients) were women, 
and 63.26% (31 patients) were men (Fig. 4). 
Figure 5 illustrates two different body compositions of cancer 
patients before starting radiotherapy.  
DISCUSSION 
Cancer induces muscle wasting and oncologic patients are at 
higher risk of malnutrition not only due to the physical and meta-
bolic effects of cancer but also because of anticancer therapies, 
as occurs after oncological surgery or during radiochemotherapy 
(3,17,18). On the other hand, it is known that the nutritional side 
effects of radiation depend on tumor location, total dose, and 
the effects of combined radiochemotherapy, with head and neck, 
digestive system, and lung cancer patients being most affected 
(19,20).



















Mean 65.10 66.75 24.63 123.82 45.51 131.92 133.19 11.29 29.02
SD 11.62 11.25 3.98 34.01 10.33 76.80 85.28 12.86 8.66
Median 66 66 24.83 121.17 45.37 114.17 109.00 6.90 29.32
IQ25 range 56.50 59.40 22.34 100.72 40.38 75.03 74.29 3.55 22.78
IQ75 range 73.50 75.50 26.26 145.87 52.00 180.77 184.37 13.90 34.43
BMI: body mass index (kg/m2); SMM: skeletal muscle surface area at L3 = Sum of spinal vertebrae, transverse abdominis, external/internal oblique, and rectus 
abdominis muscles divided by CT slice thickness (cm2); SMI: lumbar skeletal muscle index = (SMM at L3/stature)2 (cm2/m2); SAT: subcutaneous adipose tissue surface 
area at L3 = The adipose tissue between the muscle and the skin (HU -190 to -30), divided by CT slice thickness (cm2); VAT: visceral adipose tissue surface area at L3  
= Fat surrounding organs (HU -150 to –50), divided by CT slice thickness (cm2); IMAT: intermuscular adipose tissue surface area at L3 = Fat between and within the 
muscle groups (HU -190 to -30), divided by CT slice thickness (cm2). 
Figure 3.
Sex distribution of the skeletal muscle index (cm2/m2) as analyzed by CT scans. 
Amongst women with low SMI, 37.50% had a BMI ≥ 25 kg/m2, and were con-
sidered sarcopenic obese, and 12.50% had a BMI < 25 kg/m2. Amongst males, 
12.12% had a BMI < 25 kg/m2 and 33.33% had a BMI ≥ 25 kg/m2, and were also 
considered sarcopenic obese. On the other hand, 50% of women and 54.54% of 
men were not considered to be sarcopenic.
Figure 4.
Prevalence of myosteatosis (HU) as analyzed by CT scans. Myosteatosis (low mus-
cle density) was present in 89.79% of the sample. According to sex distribution, 
myosteatosis was present in 93.94% of males and 81.25% of females. On the 














Sarcopenic patients with BMI ≥ 25 kg/m2
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To date many studies have reported that malnutrition is fre-
quently found between 30% and 85% of patients with progressive 
cancer disease (3,21). In terms of health outcomes, this fact is 
associated with muscle and weight loss, reduced immune com-
petence, and higher risk of infection, psychosocial stress, lower 
quality of life, higher toxicity from antineoplastic treatments, poo-
rer survival, longer hospital stays, and increased hospital costs 
(2,3,22,23). Consequently, monitoring body composition before 
cancer treatment could be very useful to provide nutritional and 
Figure 5.
Variation of SMI, VAT, SAT, and IMAT in cancer patients before starting radiotherapy. Comparison of two cancer patients with different body 
composition using CT planning scans (A and B). A. Patient with visceral obesity, myosteatosis and low muscle mass.  : skeletal muscle;  : 
visceral adipose tissue;  : subcutaneous adipose tissue;  : intramuscular adipose tissue. B. Patient with subcutaneous obesity, myosteatosis 
and low muscle mass.  : skeletal muscle;  : visceral adipose tissue;  : subcutaneous adipose tissue;  : intramuscular adipose tissue.
medical interventions in order to optimize treatment and reduce 
toxicity levels (24,25). 
Nowadays, many studies show that the third lumbar vertebra (L3) 
is strongly correlated with total body tissue areas, and cross-sectio-
nal imaging provides an intuitive and highly differentiated analysis 
of human body composition with discrimination of specific organs 
and tissue types (13,14). Routine use of CT imaging in the general 
population has been limited by cost and the necessary exposure to 
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rely heavily on imaging techniques for diagnosis and treatment, for 
the care and radiotherapy of their patients. As body composition phe-
notypes in cancer patients have recently been associated with their 
risk for poor health outcomes, computerized tomography scans have 
emerged as a readily accessible method of assessing adipose tis-
sues and muscle mass (26,27,28), all of them being available at any 
radiotherapy department and offering important and singular images 
about body composition. 
Lean body mass in the form of skeletal muscle is the predominant 
source of protein in the body, and a major predictor of functional capa-
city, as over 99% of metabolic processes take place in this surface area 
(29). Moreover, muscle protein depletion is a hallmark of cancer ca-
chexia, a multifactorial wasting syndrome characterized by involuntary 
weight loss with ongoing loss of SMM with or without loss of fat (3,30). 
Cachexia’s wasting consequences cannot frequently be reversed by 
conventional nutrition care, and its presence may lead to functional 
impairment (3,31). Sarcopenia is a major feature of cancer cachexia 
and is related with reduced quality of life and survival in cancer patients 
(2,32,33). A meta-analysis of 38 studies found that a low skeletal 
muscle index in cancer was associated with worse survival in patients 
with solid tumors (26). On the other hand, another study shows that 
decreased muscle mass had a harmful effect against grade 3-4 neu-
tropenia and all grade 3-4 toxicities (4). Our study indicates that skeletal 
muscle abnormalities are frequently present in cancer patients, and 
according to our patients’ body composition, mean SMM was 123.81 
(± 34.01) cm2, and low SMI was present in almost half of the sample 
(46.94%) – 8 women (50%) and 15 men (45.45%). This is a very 
important fact, taking into account the mounting of scientific evidence 
to suggest that LBM may be a better predictor of drug administration 
and cancer therapies than either total bodyweight or body surface area 
(34,35). Currently there are about fourteen studies that have related 
CT-based body composition to the prevalence of dose limiting toxicity 
(DLT) or different grades of toxicity, and investigations become each 
and every day more important in this area (36). Furthermore, there 
have been reports showing the role of body composition, especially 
lean mass, on the pharmacokinetics of 5-FU (37).
On the other hand, low attenuation of muscles is a sign of trigly-
ceride accumulation in muscle cells, and has also been shown to 
be associated with systematic inflammation (a hallmark of cancer 
cachexia) (5). The pathological accumulation of fat in muscles, also 
called myosteatosis, describes an abnormal retention of lipids within 
muscle tissue and has been associated with insulin resistance as 
well as decreased muscle activity (14). In our study, mean IMAT was 
11.29 (± 12.86) cm2 and total skeletal attenuation of muscle area 
was 29.02 (± 8.66) HU. According to our findings, myosteatosis was 
present in 89.89% of cancer patients.
However, obesity is a heterogeneous condition with individual diffe-
rences in the pattern of adipose tissue deposition (6). Accumulation of 
abdominal fat, particularly in the visceral compartment, may confer the 
majority of obesity-associated health risks, being also associated with 
different types of cancers, such as colorectal or prostate malignancies 
(6,38,39). Because visceral adipose tissue (VAT), rather than subcu-
taneous adipose tissue (SAT), is recognized as the contributing factor 
in body insulin resistance, visceral abdominal obesity is viewed as the 
more clinically important type of abdominal obesity (6). Many studies 
have demonstrated a close relationship between body fat distribution 
and the occurrence of the metabolic syndrome or obesity-related 
complications, and the accumulation of heavy VAT can interrupt blood 
flow to abdominal organs and decrease organ function (40). In terms 
of fat composition the characteristics of the cancer patient presented 
in our study had an average of 131.92 (± 76.80) cm2 of SAT, and 
133.19 (± 85.28) cm2 of VAT. 
Nevertheless, low levels of muscle mass are not only seen in pa-
tients who appear cachectic, and it could also be present in individuals 
who are overweight or obese (7,9). This is due to cancer patients may 
develop simultaneous loss of skeletal muscle and gain of adipose tis-
sue, culminating in the condition of “sarcopenic obesity” (8). The com-
bination of sarcopenia and obesity has been associated with additive 
adverse effects related to physical disability in several epidemiologic 
studies (41). This dangerous term is strongly related to reduction in 
survival, worse prognosis, and increased adverse effects compared 
to sarcopenic or obese cancer patients (42). In our study, in total, 
there were 6 women (37.50%) and 11 men (33.33%) identified with 
a BMI ≥ 25 kg/m2, being sarcopenic obese. Although this was noted 
in patients across the full range of body weight, sarcopenic obesity 
was particularly noted to have a strong association with poor survival 
when compared with non-sarcopenic obesity (9).
While other anthropometric quantification methods used to diagno-
se muscle depletion, such as bioelectrical impedance analysis (BIA), 
triceps or abdominal skinfolds, or waist circumference (WC), have 
a significant inter- and intra-observer variability, serum albumin or 
prealbumin are very expensive to quantify and depend on external 
factors such as body inflammation (2). Moreover, this has limited 
sensitivity for detecting VAT, SAT, IMAT or sarcopenic obesity (12,13). 
Because of that, CT scans are presently considered the most reliable 
methods for the analysis of body composition, because they can pro-
vide important quantitative information on muscle composition and 
distribution through their high pictorial quality, spatial accuracy, site 
specificity, and the ability to measure fat and muscle content from one 
abdominal cross-sectional slice (28,43).
The limitation of our study was that the delineation of muscles and 
adipose tissue was performed by a single researcher. On the other 
hand, different consensus groups who are working on sarcopenia 
as, for example, the European Working Group on Sarcopenia in Older 
People (EWGSOP), the Foundation for National Institutes of Health Sar-
copenia Project, or the Society for Sarcopenia, Caquexia and Wasting 
Disorders, insist on the importance of evaluating muscle performance 
or muscle strength (2), which have not been collected in our patients. 
Likewise, the evaluation of body composition using CT scans may be 
a useful adjunct in managing patients with cancer, and may improve 
patient selection for therapies through the identification of high-risk 
individuals and appropriate initiation of early supportive care. 
In conclusion, our study indicates that skeletal muscle and fat ab-
normalities are frequently present in cancer patients. On the other 
hand, sarcopenia may also exist even in the presence of overweight. 
To date, many studies have highlighted the importance of assessing 
malnutrition in cancer disease, and as CT planning scans are routinely 
used in the radiotherapy department, they can be used to assess 
skeletal muscle volume as well as adipose tissue in cancer patients 
undergoing radiotherapy.
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